Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis

Journal of Health Economics

Volumn 55, Issue , 2017, Pages 139-152

  Hernández Alava, Mónica ^a   Pudney, Stephen ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Copula; Cost effectiveness; EQ 5D; Mapping; Mixture models; Ordinal response; Rheumatoid arthritis

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; PLACEBO; PREDNISOLONE; ANTIRHEUMATIC AGENT;

COST-BENEFIT ANALYSIS; DECISION MAKING; DISEASE TREATMENT; DRUG PRESCRIBING; ECONOMETRICS; HEALTH STATUS; IMMUNE SYSTEM; MAPPING; NUMERICAL MODEL;

AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FATIGUE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PAIN ASSESSMENT; RHEUMATOID ARTHRITIS; SELF REPORT; SLEEP DISORDER; STATISTICAL MODEL; VERY ELDERLY; COST BENEFIT ANALYSIS; ECONOMICS; PROCEDURES; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; FEMALE; HEALTH STATUS; HUMANS; MALE; MODELS, ECONOMETRIC; QUALITY OF LIFE; SELF REPORT; TREATMENT OUTCOME;

EID: 85026513334     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2017.06.013     Document Type: Article

References (37)

1. Agborsangaya, C.B., Lahtinen, M., Cooke, T., Johnson, J.A., Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual. Life Outcomes 12 (2014), 1–7.
2. Augustovski, F., Rey-Ares, L., Irazola, V., Garay, O.U., Gianneo, O., Fernández, G., Morales, M., Gibbons, L., Ramos-Go ni, J.M., An EQ-5D-5L value set based on Uruguayan population preferences?. Qual. Life Res. 25:2 (2016), 323–333.
3. Bedford, T., Cooke, R., Vines – a new graphical model for dependent random variables. Ann. Stat. 30 (2002), 1031–1068.
4. Brazier, J., Tsuchiya, A., Improving cross-sector comparisons: going beyond the health-related QALY. Appl. Health Econ. Health Policy 13 (2015), 557–565.
5. Brazier, J.E., Yang, Y., Tsuchiya, A., Rowen, D.L., A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures?. Eur. J. Health Economics 11:2 (2010), 215–225.
6. Bruce, B., Fries, J.F., The Stanford Health Assessment Questionnaire (HAQ): a review of its history, issues, progress, and documentation. J. Rheumatol. 30 (2003), 67–78.
7. Choy, E.H.S., Smith, C.M., Farewell, V., Walker, D., Hassell, A., Chau, L., Scott, D.L., Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann. Rheum. Dis. 67 (2008), 656–663.
8. Claxton, K., Martin, S., Rice, N., Spackman, E., Hinde, S., Devlin, N., Smith, P.C., Sculpher, M., Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol. Assess., 19(14), 2015.
9. Conigliani, C., Manca, A., Tancredi, A., Prediction of patient-reported outcome measures via multivariate ordered probit models?. J. R. Stat. Soc. Ser. A (Stat. Soc.) 178:3 (2015), 567–591.
10. Cross, M., Smith, E., Hoy, D., Carmona, L., Wolfe, F., Vos, T., Williams, B., Gabriel, S., Lassere, M., Johns, N., Buchbinder, R., Woolf, A., March, L., The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study?. Ann. Rheum. Dis. 73:7 (2014), 1316–1322.
11. Devlin, N., Brooks, R., EQ-5D and the EuroQol group: past, present and future. Appl. Health Econ. Health Policy 15 (2017), 127–137.
12. Devlin, N., Shah, K., Feng, Y., Mulhern, B., van Hout, B., Valuing health-related quality of life: an EQ-5D-5L value set for England. Technical Report 16.02., 2016, Health Economics & Decision Science, University of Sheffield.
13. Devlin, N., van Hout, B., An EQ-5D-5L Value Set for England. 2015.
14. Dolan, P., Modeling valuations for EuroQol health states. Med. Care 35 (1997), 1095–1108.
15. Fayers, P.M., Hays, R.D., Should linking replace regression when mapping from profile-based measures to preference-based measures?. Value Health 17:2 (2014), 261–265.
16. Feng, Y., Devlin, N., Shah, K., Mulhern, B., van Hout, B., New methods for modelling EQ-5D-5L value sets: an application to English data. Technical Report 16.03., 2016, Health Economics & Decision Science, University of Sheffield.
17. Gray, A.M., Rivero-Arias, O., Clarke, P.M., Estimating the association between SF-12 responses and EQ-5D utility values by response mapping?. Med. Decis. Mak. 26:1 (2006), 18–29.
18. Hernández-Alava, M., Pudney, S.E., BICOP: a command for estimating bivariate ordinal regressions with residual dependence characterized by a copula function and normal mixture marginal?. Stata J. 16:1 (2016), 159–184.
19. Hernández-Alava, M., Pudney, S.E., eq5dmap: a Stata command for mapping from 3-level to 5-level EQ-5D. Technical report., 2017, Health Economics & Decision Science, University of Sheffield.
20. Hernández-Alava, M., Wailoo, A.J., Ara, R., Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D health state utility values. Value Health 15 (2012), 550–561.
21. Hernández-Alava, M., Wailoo, A.J., Grimm, S., Pudney, S.E., Gomes, M., Sadique, Z., Meads, D., O'Dwyer, J., Barton, G., Irvine, L., EQ-5D versus 3L: the impact on cost-effectiveness. Technical Report 17.02., 2017, Health Economics & Decision Science, University of Sheffield.
22. Ikeda, S., Shiroiwa, T., Igarashi, A., Noto, S., Fukuda, T., Saito, S., Shimozuma, K., Developing a Japanese version of the EQ-5D-5L value set?. J. Natl. Inst. Public Health 64:1 (2015), 47–55.
23. Janssen, M.F., Pickard, A.S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., Swinburn, P., Busschbach, J., Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual. Life Res. 22 (2013), 1717–1727.
24. Jia, Y.X., Cui, F.Q., Li, L., Zhang, D.L., Zhang, G.M., Wang, F.Z., Gong, X.H., Zheng, H., Wu, Z.H., Miao, N., Sun, X.J., Zhang, L., Lv, J.J., Yang, F., Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual. Life Res. 23 (2014), 2355–2363.
25. Kim, S.-H., Ahn, J., Ock, M., Shin, S., Park, J., Luo, N., Jo, M.-W., The EQ-5D-5L valuation study in Korea?. Qual. Life Res. 25:7 (2016), 1845–1852.
26. Longworth, L., Rowen, D., The use of mapping methods to estimate health state utility values. Technical Report NICE DSU Technical Support Document 10, Decision Support Unit, 2011, Health Economics & Decision Science, University of Sheffield.
27. Murray, C.J.L.e., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2197–2223.
28. NICE, Guide to the methods of technology appraisal 2013. Technical report., 2013, National Institute for Health and Care Excellence.
29. Panagiotelis, A., Czado, C., Joe, H., Pair copula constructions for multivariate discrete data. J. Am. Stat. Assoc. 107 (2012), 1063–1072.
30. Pickard, A.S., Leon, M.C.D., Kohlmann, T., Cella, D., Rosenbloom, S., Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med. Care 45 (2007), 259–263.
31. Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., Prete, A.D., Cesana, G., Mantovani, L.G., Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Qual. Life Res. 22 (2013), 1707–1716.
32. Trivedi, P.K., Zimmer, D.M., Copula modeling: an introduction for practitioners. Found. Trends Econom. 1 (2005), 1–111.
33. van Hout, B., Janssen, M.F., Feng, Y.S., Kohlmann, T., Busschbach, J., Golicki, D., Lloyd, A., Scalone, L., Kind, P., Pickard, A.S., Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15 (2012), 708–715.
34. Versteegh, M.M., Vermeulen, K.M., Evers, S.M.A.A., Ardine de Wit, G., Prenger, R., Stolk, E.A., Dutch tariff for the five-level version of EQ-5D. Value Health 19:4 (2016), 343–352.
35. Wailoo, A., Hernández-Alava, M., Scott, I.C., Ibrahim, F., Scott, D.L., Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology 53 (2014), 1773–1777.
36. Wolfe, F., Michaud, K., The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology 50 (2011), 16–24.
37. Xie, F., Pullenayegum, E., Gaebel, K., Bansback, N., Bryan, S., Ohinmaa, A., Poissant, L., Johnson, J.A., A time trade-off-derived value set of the EQ-5D-5L for Canada?. Med. Care 54:1 (2016), 98–105.